However, in heterogeneous tumors in which wildtype tumor cells were admixed with STUB1-deficient cells, STUB1 deficiency strengthened IFNγ signaling, thereby enhancing the response to anti-PD-1 treatment. This evidence concerns the gene STUB1 and neoplasm.